Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight

(Albany, United States) DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape.
It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Urothelial Carcinoma Pipeline Report
• DelveInsight's Urothelial Carcinoma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
• The leading Urothelial Carcinoma Companies working in the market include MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others
• Promising Urothelial Carcinoma Pipeline Therapies in the various stages of development include Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others.
• April 2024: Seagen Inc. announced a study of Phase 2 clinical trials for disitamab vedotin and pembrolizumab. This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
• April 2024: Hoffmann-La Roche announced a study of Phase 1 clinical trials for Atezolizumab, Enfortumab Vedotin, Niraparib, and Gemcitabine. A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status).

Request a sample and discover the recent advances in Urothelial Carcinoma Treatment Drugs @ Urothelial Carcinoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

In the Urothelial Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Urothelial Carcinoma NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Urothelial Carcinoma Overview
Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. Urothelial carcinomas are the fourth most common tumors after prostate (or breast cancer), lung and colorectal cancer. This carcinoma is derived from the urothelium of the upper urinary tract (renal pelvis and ureter) or lower urinary tract (urinary bladder).

Find out more about Urothelial Carcinoma Therapeutics Assessment @ Urothelial Carcinoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Urothelial Carcinoma Emerging Drugs Profile
• Pemazyre (pemigatinib): Incyte
Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

• Cetrelimab: Janssen Research and Development
Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio.

Urothelial Carcinoma Pipeline Therapeutics Assessment
There are approx. 40+ Urothelial Carcinoma companies which are developing the Urothelial Carcinoma therapies. The Urothelial Carcinoma companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include Janssen Research and Development.

DelveInsight's Urothelial Carcinoma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Urothelial Carcinoma Products have been categorized under various Molecule types such as
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Learn more about the emerging Urothelial Carcinoma Pipeline Therapies @ Urothelial Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Urothelial Carcinoma Pipeline Report
• Coverage- Global
• Urothelial Carcinoma Companies- MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others.
• Urothelial Carcinoma Pipeline Therapies- Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others
• Urothelial Carcinoma Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for new drugs for Urothelial Carcinoma Treatment, Visit @ Urothelial Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Urothelial Carcinoma Executive Summary
3. Urothelial Carcinoma: Overview
4. Urothelial Carcinoma Pipeline Therapeutics
5. Urothelial Carcinoma Therapeutic Assessment
6. Urothelial Carcinoma- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase III)
8. Cetrelimab: Janssen Research and Development
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Vactosertib: MedPacto
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. MV NIS: Vyriad
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Urothelial Carcinoma Key Companies
24. Urothelial Carcinoma Key Products
25. Urothelial Carcinoma- Unmet Needs
26. Urothelial Carcinoma- Market Drivers and Barriers
27. Urothelial Carcinoma- Future Perspectives and Conclusion
28. Urothelial Carcinoma Analyst Views
29. Urothelial Carcinoma Key Companies
30. Appendix

For further information on the Urothelial Carcinoma Pipeline therapeutics, reach out to Urothelial Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Biliary Stents Market: https://www.delveinsight.com/report-store/biliary-stents-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Chemotherapy Induced Febrile Neutropenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
• Chronic Inducible Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Refractory Gout Market: https://www.delveinsight.com/report-store/chronic-refractory-gout-market
• Clostridium Difficile Infections Cdi Market: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
• Colorectal Cancer Crc Market: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market
• Contact Dermatitis Market: https://www.delveinsight.com/infographics/contact-dermatitis-market#:~:text=The%20market%20size%20of%20Contact,USD%207%2C831%20Million%20in%202017.
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
• Ehlers-danlos Syndrome Market: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market
• Gouty Arthritis Market: https://www.delveinsight.com/report-store/gout-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Higher-risk Chronic Myelomonocytic Leukemia Market: https://www.delveinsight.com/report-store/higher-risk-chronic-myelomonocytic-leukemia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Leber's Hereditary Optic Neuropathy Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Metachromatic Leukodystrophy Market Research Report: https://www.delveinsight.com/report-store/metachromatic-leukodystrophy-mld-market
• Neuroprosthetics Market: https://www.delveinsight.com/report-store/neuroprosthetics-market-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.